DENTSPLY SIRONA (XRAY) Projected to Release Quarterly Earnings on Thursday

DENTSPLY SIRONA (NASDAQ:XRAYGet Free Report) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $0.3480 per share and revenue of $889.2140 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

DENTSPLY SIRONA (NASDAQ:XRAYGet Free Report) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The business had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. DENTSPLY SIRONA’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 EPS. On average, analysts expect DENTSPLY SIRONA to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DENTSPLY SIRONA Price Performance

NASDAQ XRAY opened at $14.13 on Tuesday. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. The firm has a market capitalization of $2.83 billion, a price-to-earnings ratio of -4.49, a price-to-earnings-growth ratio of 1.59 and a beta of 0.85. The company has a 50 day simple moving average of $11.52 and a 200-day simple moving average of $11.86. DENTSPLY SIRONA has a 52-week low of $9.40 and a 52-week high of $14.86.

Wall Street Analysts Forecast Growth

XRAY has been the topic of several research reports. BMO Capital Markets assumed coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $12.00 price objective on the stock. UBS Group decreased their target price on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Barclays lowered their price target on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a report on Thursday, June 4th. Citigroup assumed coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price target on the stock. Finally, Piper Sandler lifted their price objective on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Three equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $13.46.

Check Out Our Latest Stock Report on DENTSPLY SIRONA

Insiders Place Their Bets

In related news, Director Brian T. Gladden purchased 9,985 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was bought at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the purchase, the director owned 61,849 shares in the company, valued at $619,726.98. The trade was a 19.25% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Michael J. Barber purchased 15,175 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $9.88 per share, with a total value of $149,929.00. Following the purchase, the director owned 55,943 shares in the company, valued at $552,716.84. This represents a 37.22% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 35,160 shares of company stock valued at $351,179 over the last quarter. Insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of large investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of DENTSPLY SIRONA in the first quarter worth $26,000. Caitong International Asset Management Co. Ltd grew its stake in DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 2,122 shares during the last quarter. Kestra Advisory Services LLC bought a new position in DENTSPLY SIRONA in the 4th quarter worth $56,000. Persistent Asset Partners Ltd acquired a new position in DENTSPLY SIRONA during the 4th quarter worth $98,000. Finally, Compound Planning Inc. acquired a new position in DENTSPLY SIRONA during the 4th quarter worth $117,000. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

(Get Free Report)

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

Featured Stories

Earnings History for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.